Antipsychotic drugs do most of their work in the brain, but they also leave behind in the bloodstream a trail of hundreds of chemicals that may be used in the future to direct better treatment for schizophrenia and other psychiatric conditions, say Duke University Medical Center researchers.
Get the full story...
Curidium Medica Plc, (LSE: CUR), the personalized medicine company focused on bringing the right drug to the right patient, announced on May 14th it has developed a blood diagnostic test that can sub-classify patients with schizophrenia/bipolar disorder into one of four subgroups.
Get the full story...
Research by the World Health Organization (WHO) has suggested that the course and symptomatic expression of schizophrenia is relatively more benign in developing societies. However, a new study from Current Anthropology challenges this assumption, comparing biological and cultural indicators of schizophrenia in urban, Western societies with study data from the island of Palau, which has one of the highest rates of schizophrenia diagnosis in the world today.
Read the full story
